Epigenomics reported Q1/2019 sales of €331k (7% YoY), driven largely by a 198% YoY increase in product revenue, which was in part offset by lower licensing revenue due to the recently announced termination of the collaboration with Chinese licensing partner BioChain. We expect solid underlying growth momentum to continue throughout 2019, with back-end loaded revenue generation in Q3 and Q4 fuelled by a number of commercial as well as regulatory catalysts that can unlock significant sales potenti ....
16 May 2019
Key catalysts to fuel growth throughout 2019
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Key catalysts to fuel growth throughout 2019
Epigenomics AG (0QXH:LON) | 0 0 0.0% | Mkt Cap: 24.5m
- Published:
16 May 2019 -
Author:
Martin Piehlmeier -
Pages:
5
Epigenomics reported Q1/2019 sales of €331k (7% YoY), driven largely by a 198% YoY increase in product revenue, which was in part offset by lower licensing revenue due to the recently announced termination of the collaboration with Chinese licensing partner BioChain. We expect solid underlying growth momentum to continue throughout 2019, with back-end loaded revenue generation in Q3 and Q4 fuelled by a number of commercial as well as regulatory catalysts that can unlock significant sales potenti ....